Program

New Cancer Targets – NCT Conference

September 23rd – 24th, 2013

Lecture Hall
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
69120 Heidelberg

September 23rd, 2013

08:45-09:00   Opening Remarks

Session 1 – Integrative Radiotherapy

09:00-09:30 Combining Stroma-Targeted Therapies with Radiation to Prevent Resistance (Dan G. Duda, MGH, Harvard)
09:30-10:00 Intratumoral Heterogeneity: Hypoxia and Radiotherapy (Jens Overgaard, Aarhus University Hospital)
10:00-10:30 The Tumour Microenvironment in Radiotherapy. Approaches to the Problem (Gillies McKenna, Gray Institute, Oxford)

10:30-11:00 Coffee Break & Networking

11:00-11:30 HITting the Target (Jürgen Debus, HIT and University Hospital Heidelberg)

Session 2 – Drugging the Cancer Genome

11:30-12:00 Functional Genomics, Experimental Models and Cancer (William Hahn, Dana-Farber Cancer Institute / Broad Institute)
12:00-12:30 Molecular Stratification of Cancer in the Clinical Setting (David Gonzales, The Institute of Cancer Research)
12:30-13:00 Altered Transcriptional and Epigenetic Control in Acute Myeloid Leukemia: Mechanisms and Novel Therapeutics (Brian Huntly, Cambridge Institute for Medical Research)

13:00-14:00 Lunch & Networking

14:00-14:30 Discovery of Drug Sensitizing Genotypes in Cancer Cells (Mathew Garnett, Sanger Institute)
14:30-15:00 Modeling Human Cancers in The Mouse (Mario Capecchi, University of Utah School of Medicine)
15:00-15:30 Towards Individualized Immunotherapy (Ugur Sahin, TRON and Mainz University Medical Center)
15:30-16:00 "Liquid Biopsy" Current Status and Future Perspective (Klaus Pantel, Institute for Tumor Biology, UKE Hamburg)
16:30-16:30 Beyond the CENTRIC Trial - Integrin Targeting for Tumor Therapy Sensitization (Nils Cordes, OncoRay, TU Dresden)

16:30-18:00 Coffee Break & Poster Session
18:00-19:00 Welcome Reception
19:30  Speakers’ dinner

September 24th, 2013

Session 3 – Innovative Anti-Cancer Targets

08:00-08:30 Adaptive Mechanisms to Anti-Vascular Therapy (Rolf Bjerkvig, University of Bergen)
08:30-09:00 Novel Targets and Strategies in Gliomas (Patrick Wen, DFCI)
09:00-09:30 Targeting PI3K Pathway Resistance in Glioblastoma (W.K. Alfred Yung, MD Anderson)
09:30-10:00 Novel Therapeutic Interventions in Glioblastoma (Thomas Würdinger, VU Cancer Center)

10:00-10:30 Coffee Break & Networking

10:30-11:00 New Therapeutic Targets in Childhood Brain Tumors (Stefan Pfister, DKFZ and University Hospital Heidelberg)
11:00-11:30 The Modern MS-Based Proteomics Toolbox and its Application in Cancer (Matthias Mann, Max Planck Institute of Biochemistry)

Session 4 – Anti-Cancer Immunotherapy

11:30-12:00 Cancer Immunoediting and a Genomics Approach to Cancer Immunotherapy (Robert Schreiber, Washington University School of Medicine)
12:00-12:30 Towards Personalized Immunotherapy of Cancer (Hans-Georg Rammensee, University of Tübingen)
12:30-13:00 Towards more Efficient Immunotherapy of Established Lesions Caused by High Risk HPV (Cornelis Melief, Leiden University Medical Center

13:00-14:00 Lunch & Networking

14:00-14:30 Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells (Steve Feldman, Center for Cancer Research, National Cancer Institute)
14:30-15:00 Cancer Immunometabolism: IDO Pathway and its Therapeutic Correction (George Prendergast, Lankenau Institute for Medical Research)
15:00-15:30 Manipulation of The Tumor Micro Environment by Depletion of Tumor Associated Macrophages (Klaus Bosslet, Roche)
15:30-16:00 Multiple Strategies for Targeting HER2-Positive Breast Cancer (Gail Lewis Phillips, Research Oncology, Genentech)

16:00-16:30 Coffee Break & Networking

Session 5 – Cancer Prevention, Early Detection and Outcomes

16:30-17:00 Genetic Predisposition to Prostate Cancer and Application to Targeted Screening (Rosalind Eeles, Institute of Cancer Research)
17:00-17:30 Systems Approaches to Blood Based Cancer Biomarkers (Sam Hanash, Fred Hutchinson Cancer Research Center)
17:30-18:00 The Role of Physical Activity in Cancer Prevention and Survival (Kerri Winters-Stone, Oregon Health & Science University)
18:00-18:30 20 Years of EPIC Cohort Study: News and Next Steps (Elio Riboli, Imperial College)
18:30  Meeting Adjourns

to top
powered by webEdition CMS